德国主动脉瓣注册研究:18010例TAVI与sAVR五年结局
倾向评分匹配后,TAVI组5年全因死亡率显著高于sAVR组(41.9%对30.3%,HR 1.51,95%CI 1.35-1.68,P<0.0001),TAVI组新起搏器植入率亦更高。
要点
- 匹配后TAVI组5年全因死亡风险显著高于sAVR组(HR 1.51)。
- TAVI组术后新起搏器植入率24.6%,高于sAVR组的11.0%。
- 两组院内卒中、院内心梗及透析情况无重大差异。
核心结论
- 5年随访显示TAVI患者较sAVR患者年龄更大且STS评分更高。
- 倾向评分匹配后,早期代TAVI假体与sAVR相比5年全因死亡率显著更高。
研究设计与样本
- 患者于2011至2012年在德国中部92个中心接受治疗,采用最近邻倾向评分匹配,匹配后每组1820例。
主要发现
- TAVI组年龄80.9±6.1岁高于sAVR组68.5±11.1岁,STS评分6.3±4.9高于2.6±3.0(均P<0.001)。
- 未匹配亚组中TAVI组5年全因死亡率49.8%,sAVR组16.5%(P<0.0001)。
- 匹配组5年随访TAVI组死亡763例(41.9%),sAVR组552例(30.3%),HR 1.51(95%CI 1.35-1.68),P<0.0001。
关键数值与推荐
- 新起搏器植入:TAVI组448例(24.6%),sAVR组201例(11.0%),P<0.0001。
- 院内卒中、院内心肌梗死及临时与长期透析两组间无重大差异。
临床怎么用
- 解读该结果需考虑TAVI使用的是早期代假体,不能直接外推至当代TAVI器械与患者选择。
- 对年龄较轻、STS评分较低的患者,sAVR在5年生存方面仍具优势,决策应结合个体风险。
局限性
- 为观察性队列研究,即使经倾向评分匹配仍可能存在残余混杂。
- TAVI组使用早期代假体,结果不能直接推广至当前器械与技术。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To determine the 5-year outcome in patients treated by isolated transcatheter aortic valve implantation (TAVI) or surgical aortic valve replacement (sAVR)-a prospective observational cohort study. METHODS: A total of 18 010 patients were included (n = 8942 TAVI and n = 9068 sAVR) in the German Aortic Valve Registry (GARY) who were treated in 2011 and 2012 at 92 sites in central Germany. Eligible patients with TAVI and sAVR were matched using propensity scores in a nearest-neighbour approach. Patients with repeat procedures or unequivocal indication for one treatment option (e.g. frailty) were excluded (n = 4785 for TAVI and n = 2 for sAVR). This led to 13 223 patients (4157 TAVI and 9066 sAVR) as an unmatched subcohort. The main outcome measure was the 5-year all-cause mortality. RESULTS: TAVI patients were significantly older (80.9 ± 6.1 vs 68.5 ± 11.1 years, P < 0.001), had a higher Society of Thoracic Surgeons (STS) score (6.3 ± 4.9 vs 2.6 ± 3.0, P < 0.001) and a higher 5-year all-cause mortality (49.8% vs 16.5%, P < 0.0001). There was no major difference in in-hospital stroke, in-hospital myocardial infarction, or temporary and chronic dialysis. In the propensity score-matched group (n = 3640), there were 763 deaths (41.9%) among 1820 TAVI patients compared with 552 (30.3%) among 1820 treated with sAVR during the 5-year follow-up (hazard ratio 1.51, 95% confidence interval 1.35-1.68; P < 0.0001). New pacemaker implantation was performed in 448 patients (24.6%) after TAVI and in 201 (11.0%) after sAVR (P < 0.0001). CONCLUSIONS: The 5-year follow-up data show that TAVI patients were significantly older and had a higher STS score than sAVR patients. After propensity score matching, TAVI with early-generation prosthesis was associated with significantly higher 5-year all-cause mortality than sAVR.
引用
- Beyersdorf F, Bauer T, Freemantle N, et al. Five-year outcome in 18 010 patients from the German Aortic Valve Registry. Eur J Cardiothorac Surg. 2021. PMID: 33942061. doi:10.1093/ejcts/ezab216
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。